Presynaptic dopaminergic agonists modify brain glucose metabolism in a way similar to the neuroleptics.
The effects of the (+) and (-) enantiometers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), 9,10-didehydro-6-methyl-8 beta-(2-pyridylthiomethyl)ergoline (CF 25-397) and 6,7-dihydroxy-2-dimethyl-aminotetralin (TL 99), three agonists of the postulated presynaptic dopamine receptor, on the pattern of brain glucose metabolism were studied using the autoradiographic technique of Sokoloff et al. [19]. It was found that these drugs modify brain glucose metabolism in a way similar to the neuroleptics but different from postsynaptic agonists. These results support the suggestion that these drugs could represent a new type of neuroleptic.